Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma
Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma
复制标题
DOI：
10.1097/pai.0000000000000140
复制
发表时间：
2015-11-01
影响因子：
1.6
通讯作者：
Yu, Eunsil
中科院分区：
文献类型：
--
作者：
Eom, Dae-Woon;Hong, Seung-Mo;Yu, Eunsil
背景：小肠腺癌是一种罕见的人类恶性肿瘤。根据肿瘤干细胞(CSC)假说，只有一小部分肿瘤细胞具有启动和促进肿瘤生长的能力。CD44v6、CD133、CD166和ALDH1被认为是胃肠道恶性肿瘤的CSC标志物。然而，它们对SIAC的影响仍不明朗。材料与方法：采用免疫组织化学方法对191例手术切除的SIAC进行CD44、CD133、CD166和ALDH1的免疫组织化学检测。结果：CD44v6、CD133、CD166和ALDH1的表达分别为25例(13.5%)、58例(30.7%)、82例(44.1%)和63例(33.3%)。CD44v6(+)与血管性肿瘤侵袭有关(P=0.023)。CD133(+)与肿瘤的组织学亚型呈负相关(P=0.085)。单因素(P=0.016)和多因素(P=0.048；COX风险比，2.403)分析表明，CD44v6(+)/CD133(+)表达与SIAC患者的预后显著相关。结论：联合检测CD133和CD44v6的表达可作为预测SIAC预后的有用工具。
Background:Small intestinal adenocarcinoma (SIAC) is a rare human malignant tumor. According to the cancer stem cell (CSC) hypothesis, only a small subpopulation of tumor cells has the ability to initiate and increase tumor growth. CD44v6, CD133, CD166, and ALDH1 have been proposed to be putative CSC markers in gastrointestinal malignancies. However, their implications in SIAC still remain unclear. We aimed to investigate the expressions of CD44v6, CD133, CD166, and ALDH1 and evaluate their relationships with clinicopathologic parameters including the survival data in SIACs.Materials and Methods:Immunohistochemical analysis for CD44, CD133, CD166, and ALDH1 was performed using tissue microarrays for 191 surgically resected SIACs.Results:CD44v6, CD133, CD166, and ALDH1 expression was found in 25 (13.5%), 58 (30.7%), 82 (44.1%), and 63 (33.3%) cases, respectively. CD44v6(+) was correlated with vascular tumor invasion (P=0.023). CD133(+) was marginally correlated with the histologic subtype of the tumors (P=0.085). Combined CD44v6(+)/CD133(+) was observed in 11 (5.9%) and was associated with a significantly worse survival rate by univariate (P=0.016) and multivariate (P=0.048; Cox hazard ratio, 2.403) analyses.Conclusions:Evaluation of the combined CD133 and CD44v6 expression could be a useful tool for predicting a poor outcome in patients with SIAC.